Biotech company Oncologie announced a clinical trial cooperation agreement with Merck (MSD) to evaluate the combination therapy of anti-phosphatidylserine (PS) antibody Bavituximab with Merck’s anti-PD-1 therapy Keytruda. The efficacy and safety of advanced gastric cancer or esophagogastric junction cancer.
Under the terms of the agreement, Oncologie will conduct a one-arm open-label phase 2 clinical trial to evaluate the efficacy and safety of this combination therapy for patients with advanced gastric cancer and esophagogastric cancer. Experienced a failed pre-therapy. This clinical study will recruit approximately 80 related cancer patients in the United States, the United Kingdom, South Korea and Taiwan in the second half of 2019.
Bavituximab is a chimeric monoclonal antibody that targets phosphatidylserine (PS). PS is a phospholipid that is exposed to the surface of stress cells in tumors and their stroma. Bavituximab blocks the binding of PS to a variety of immune cell receptors, including TIM and TAM, and reverses the PS-mediated immunosuppressive process. It has been demonstrated that antibodies targeting PS can alter the function of immune cells in tumors and stimulate the performance of multiple immune activation and anti-tumor immune responses.
This mechanism also allows other anticancer therapies to attack tumors more effectively and without restriction. Importantly, Bavituximab demonstrated its controlled safety and tolerability in clinical trials completed to date.
Keytruda is a PD-1 monoclonal antibody developed and produced by Merck (MSD). This PD-1 inhibitor blocks the binding of the PD-1 receptor on the surface of T cells to its ligand, activates T cells, and causes them to attack tumors. Keytruda was approved by the US FDA in 2014 for the treatment of advanced, inoperable, and drug-resistant melanoma, and the scope of Keytruda’s treatment of other cancers is expanding year by year.
“Stomach cancer is a major medical need that has not yet been met in many parts of the world. We are committed to understanding the clinical benefits of Bavituximab and KEYTRUDA in this difficult-to-treat cancer,” said Dr. Laura Benjamin, founder and CEO of Oncologie.
Founded in 2018, Oncologie is headquartered in Boston, USA, and is a global leader in innovative drug therapy for cancer immunotherapy. The company is dedicated to the discovery and development of new drugs for combination therapy with tumor immunity. With the academic expertise and rich business experience of Oncologie, Oncologie has established a group of new drug candidates with global intellectual property and highly differentiated.
Oncologie’s product candidates include a new mechanism of First-in-class drugs and Best-in-class drugs for improved and improved existing drugs, as well as a companion diagnostic platform for tumor immunotherapy. Dinghang Medicine currently has three clinical products, mainly covering liver cancer, stomach cancer, lung cancer, melanoma and other solid tumor indications.
About Merck (MSD)
Established in 1891, Merck is headquartered in Whitehouse, New Jersey, USA. It is one of the world’s largest pharmaceutical companies and a global leader in healthcare. The group focuses on innovative pharmaceuticals, life sciences and cutting-edge functional materials technologies.
Merck is always driven by technology to create value for patients and customers. Merck’s business is divided into four major branches: the Merck Serono business branch, the consumer health business branch, the Merck Millipore business branch, and the functional materials business branch.